Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2018 Jun 26;8:9705. doi: 10.1038/s41598-018-27735-0

Synthesis of Pure Enantiomers of Titanium(IV) Complexes with Chiral Diaminobis(phenolato) Ligands and Their Biological Reactivity

Maya Miller 1, Edit Y Tshuva 1,
PMCID: PMC6018713  PMID: 29946136

Abstract

Racemic and enantiomerically pure titanium(IV) complexes with ortho-brominated or para-nitrated chiral diaminobis(phenolato) ligands were prepared with NH and NMe cyclohexyldiamino bridges through ligand to metal chiral induction. The hydrolytic behavior of the complexes was evaluated, identifying the N-methylated complex as the most stable. A representative NH complex hydrolyzed to first give a dimeric structure in solution as deduced by NMR diffusion measurements, followed by formation of clusters with higher nuclearity, as was supported by X-ray characterization of a tetranuclear cluster obtained in trace amounts following 30 days in water solutions. The cytotoxicity of the enantiomerically pure and racemic complexes was measured on HT-29 human colon cancer cell line based on the MTT assay; all stereochemical configurations of the N-methylated complex were inactive, whereas for the NH complexes, the racemic mixtures were mostly inactive but the pure enantiomers exhibited similarly high cytotoxicity, supporting a polynuclear active species. Analysis of the two enantiomers of the most active brominated complex for their cytotoxicity on human ovarian A2780, cisplatin resistant A2780cp and multi-drug-resistant A2780adr cell lines as well as for their apoptosis induction on the A2780 line revealed similar reactivity, supporting a similar mechanism for the two enantiomers.

Introduction

Titanium(IV) compounds were the first non-platinum based metallodrugs entering clinical trials for treatment of cancer17. Two classes of compounds based on cyclopentadienide and diketonato ligands exhibited a wide range of activity and mild toxicity in vivo821, but their rapid hydrolysis under biological environment to form multiple unidentified products hampered further development14,22,23. Later “salan” type diaminobis(phenolato) Ti(IV) compounds (Fig. 1) showed: (a) markedly improved hydrolytic stability eventually giving defined polynuclear hydrolysis products, and (b) a wide range of activity both in vitro and in vivo, with no sign of toxicity to treated animals13,2434. Wide structure-activity relationship studies pointed to a negative effect of steric bulk and a positive effect of ortho-halogenation on hydrolytic stability and cytotoxicity.

Figure 1.

Figure 1

Salan titanium(IV) complexes.

The salan type Ti(IV) complexes are chiral, exhibiting C2 or C1 symmetry. Therefore, when considered for medicinal applications, the evaluation of the biological activity of the pure enantiomers as well as their racemic mixture is essential35,36. In previous studies, employing chiral trans-cyclohexyldiamine- and bipyrrolidne-based ligands induced ligand-to-metal chiral induction affording enantiomercally pure compounds that were analyzed for cytoxicity3740. In general, the enantiomerically pure forms of cyclohexyl-based NH complexes gave higher cytotoxicity relative to that of the racemic mixture37; however, for related active N-Me complexes, the racemic mixture was generally more active than the pure enantiomers38. In contrast, for the bipyrrolidine-based complexes, the racemate was inactive whereas its enantiomerically pure isomers had similar biological activity40. Following studies suggested that the hydrolysis products participate as the active specie inside the cell4144, providing an explanation to the different reactivity of racemates relative to that of the enantiomerically pure forms; whereas pure enantiomers gave homochiral dimeric clusters, the racemic mixtures produced heterochiral diastereomeric dimers37,40. This paper presents structure-activity relationship studies of differently substituted cyclohexyl-based complexes, analyzed as enantiomerically pure and as racemic. Preliminary mechanistic studies suggest a similar mode of action for the two active enantiomers.

Results and Discussion

Synthesis and Characterization

Three sets of salan cyclohexyldiaminobis(phenolato) Ti(IV) complexes were synthesized according to a published procedure; each was produced as two separate enantiomers (Δ or Λ at metal) through ligand-to-metal chiral induction from optically pure trans-1,2-diaminocyclohexane (R,R or S,S at ligand, respectively)4547, and as a racemic mixture (Δ + Λ at metal) starting from the racemic form of the starting material (Fig. 2). The compounds differed in the aromatic substitution and the diamino bridge. Ortho-bromination was selected for enhancing hydrolytic stability as reported previously26,3234,40, and para-nitration was selected for improving solubility26,34.

Figure 2.

Figure 2

Titanium(IV) complexes of chiral cyclohexyldiaminobis(phenolato) ligands.

Ligands L1–3H2 were synthesized according to a published procedures3739,48; ligand L1,2H2 were obatined by a condensation reaction between the substituted benzaldehyde and trans-diaminocyclohexane, and L3H2 was obtained by methylation of L1H2 with formaldehyde. The ligands were characterized by NMR and optical rotation. The corresponding Ti(IV) complexes were produced by reacting L1–3H2 with Ti(OiPr)4 in THF, at room temperature, for 12–72 hours3739. 1H NMR confirmed that the desired complex had been obtained quantitatively in >95% optical purity.

Single crystals suitable for X-ray crystallography were obtained at −30 °C for three compounds: rac-L1Ti(OiPr)2 crystallized from diethyl ether, and rac-L3Ti(OiPr)2 and S,S,Λ-L3Ti(OiPr)2 crystallized from a mixture of hexane and dichlormethane, the latter confirmed the aforementioned chiral induction. The structures are presented in Fig. 3 (Supplementary Table S1). All structures featured a C2 symmetry, similarly to previously reported related Ti(IV) salan compounds3740. The Ti(IV) center exhibited an octahedral geometry, whereby the phenolato oxygen atoms were in a trans configuration and the isopropoxo groups were in a cis orientation.

Figure 3.

Figure 3

ORTEP presentations of rac-L1Ti(OiPr)2 (left), rac-L3Ti(OiPr)2 (middle) and S,S,Λ-L3Ti(OiPr)2 (right) with 50% probability ellipsoids; H atoms were omitted for clarity. Selected bond lengths [Å] and angles [°] for the three compounds respectively: Ti-O(1) 1.950(2), 1.930(4), 1.914(2), Ti-O(3) 1.791(2), 1.800(4), 1.817(2), Ti-N(1) 2.250(2), 2.324(4), 2.360(2), O(1)-Ti-O(2) 159.56(8), 165.95(2), 169.20(7), O(3)-Ti-O(4) 105.92(1), 106.77(2), 106.78(8), N(1)-Ti-N(2) 75.31(8), 74.42(2), 73.94(7).

Hydrolysis

The comparative hydrolytic stability was assessed using 1H NMR as previously described25,26, adding 10% D2O (>1000 equivalents) to THF-d8 solutions of the compounds and monitoring the signals corresponding to the iso-propoxo labile ligands overtime. All experiments were conducted on the S,S,Λ- stereoisomers. The t12 values are presented in Table 1.

Table 1.

t12 values for hydrolysis of the labile ligands of L1–3Ti(OiPr)2 at 1:9 D2O/THF-d8 solution at room temperature based on pseudo first order fit and relative IC50 [μM] values for the complexes and cisplatin toward human colon HT-29 cancer cell line (standard deviation of means were calculated for at least 3 repeats); ameasured on the S,S,Λ-stereoisomer.

Complex t12a [hr] IC50 [μM]
Racemic R,R S,S
L1Ti(OiPr)2 4 Inactive 4.1 ± 0.8 4.9 ± 1.4
L2Ti(OiPr)2 14 Inactive 4.2 ± 1.8 4.6 ± 1.5
L3Ti(OiPr)2 385 Inactive Inactive Inactive
Cisplatin 11.1 ± 0.456 [μM]

In agreement with previous studies32,37,38,40, the most hydrolytically stable compound was the N-methylated complex L3Ti(OiPr)2. Comparing the stability of the two NH compounds, similar stability, or even slightly higher stability for the nitrated compound implied that the ortho-bromination or the electron withdrawal by the nitro groups had a smaller effect on stability relative to that of the secondary amine, whereby added stability was provided by the cyclohexyl group relative to that of the ethylenediamino-based counterparts previously described26,32,3740. Inspecting the 1H NMR of the product of the hydrolysis of S,S,Λ-L1Ti(OiPr)2, six aromatic signals evinced that a product of high symmetry was obtained, presumably dimeric37,40. The more complex corresponding spectrum of the hydrolysis product of the racemic complex implied that a mixture of homo- and hetero-chiral clusters had been obtained (Supplementary Figs. S1 and S2)37,40.

To gain more structural information on the hydrolysis product of L1Ti(OiPr)2, the compound (S,S,Λ-stereoisomer) was reacted with water (>10,000 equivalents) for 30 days and the product was re-dissolved in diethyl ether and allowed to crystallize. Single crystals suitable for X-ray crystallography were obtained in trace amounts, and the structure is depicted in Fig. 4 (Supplementary Table S2). The structure (R 3¯ c space group) features a tetrameric species of the type Ti4(μ-O)4(S,S-L1)4 with four titanium centers bridged by oxo atoms, each metalo center binding a salan ligand with the phenolato donors having shifted to a cis orientation. The bond lengths and angles were generally similar to those of known related compounds37,43,49,50. As this structure should yield twelve aromatic signals in the 1H NMR due to its C2 symmetry, it is evident that the tetrameric complex is not the main product obtained in the hydrolysis reaction described above.

Figure 4.

Figure 4

ORTEP presentation of Ti4(μ-O)4(S,S-L1)4 at 50% probability ellipsoids; H atoms and solvent were omitted for clarity. Selected bond lengths [Å] and angles [°]: Ti(2)-O(7) 1.820(1), Ti(2)-O(6) 1.911(3), Ti(2)-N(3) 2.294(4), O(7)-Ti(2)-O(4) 92.7(2), O(5)-Ti(2)-O(6) 94.1(2), N(3)-Ti(2)-N(4) 74.4(2).

To shed more light on the possible hydrolysis products obtained in solution, diffusion NMR measurements were applied on S,S,Λ-L1Ti(OiPr)2 upon addition of water using diffusion order spectroscopy (DOSY), whereby the diffusion coefficient (D) derived is proportional to the compound size (Table 2, Supplementary Fig. S3)5153. Within 24 hours from water addition, the dominant species was a dinuclear compound, in agreement with previous studies on related salan diaminocyclohexyl-based complexes37,40 and in correlation with the aforementioned 1H NMR spectrum of the hydrolysis reaction. Prolonged incubation in water solutions gave indication of further decomposition to give products of higher nuclearity in trace amounts. It is plausible that the dimer forming following water replacement of the isopropoxo ligands further reacts in an associative mechanism as previously suggested, to give the tetranuclear species as implied by the cis configuration of the phenolato units25.

Table 2.

Diffusion coefficients (D) values [10−10 m2/s] for S,S,Λ-L1Ti(OiPr)2 before and after addition of water; athe main product (D = 4.436 10−10 m2/s) was accompanied by another product, presumably trimeric, in trace amounts.

Time [h] D [10−10 m2/s]
0 5.572
24 4.436
48 4.436; 4.335a

Cytotoxicity

The anti-proliferative activity of the compounds was evaluated on human colon HT-29 cancer cells by the MTT (methylthiazolyldiphenyl-tetrazolium) assay as previously described54. The results are illustrated in Fig. 5 and a summary of the relative IC50 values is provided in Table 1.

Figure 5.

Figure 5

Dependence of HT-29 cell viability based on the MTT assay following a three days incubation period on added concentration of L1Ti(OiPr)2 (a); L2Ti(OiPr)2 (b) and L3Ti(OiPr)2 (c) presented on a logarithmic scale. Standard error of means were determined by a nonlinear regression of a variable slope (four parameters) model by Graph Pad Prism5.0 program for at least 9 repeats.

Inspecting the reactivity of L1,2Ti(OiPr)2, both with NH donors, no biological activity was detected for rac-LTi(OiPr)237, whereas for each, the enantiomerically pure R,R,Δ- and S,S,Λ-LTi(OiPr)2 had similarly high cytotoxicity with no significant difference, in accordance with previous observations40. Although the nitration was presumed to increase solubility as is also manifasted by increased activity relative to other para-substituted derivatives26,34,37, the maximal inhibition obtained by L2Ti(OiPr)2 is slightly lower. Inspecting the reactivity of L1,3Ti(OiPr)2, both with o-Br, it is evident that the N-methylation reduced the activity also for the enantiomerically pure forms38,40. This observation may be explained by the added steric influence of the N-Methylated cyclohexyl ring together with the steric aromatic substitutions, overall creating sufficient bulk to abolish the activity. Similar effect was obtained for complexes with non chiral ligands as previously described32.

The most active L1Ti(OiPr)2 was selected for further studies, aiming to investigate possible differences between the two enantiomers. Thus, cell viability studies were performed for the two enantiomers based on the MTT assay on human ovarian A2780 and its resistance lines: cisplatin-resistant human ovarian A2780cp and multi-drug-resistant (MDR) human ovarian A2780adr. The results are illustrated in Fig. 6 and a summary of the relative IC50 values is provided in Table 3. Marked activity was obtained for all lines tested; importantly, similar activity was recorded for the two enantiomers on all lines, implying that there are no stereospecific interactions that are essential for overpassing drug resistance.

Figure 6.

Figure 6

Dependence of ovarian carcinoma cancer cell lines (A2780: red, A2780cp: green, A2780adr: blue) cell viability based on the MTT assay following a three days incubation period on added concentration of R,R,Δ- (continuous line)/S,S,Λ- (dashed line)L1Ti(OiPr)2 presented on a logarithmic scale. Standard error of means were determined by a nonlinear regression of a variable slope (four parameters) model by Graph Pad Prism5.0 program for at least 9 repeats.

Table 3.

Relative IC50 [μM] values for complexes R,R,Δ/S,S,Λ-L1Ti(OiPr)2 toward human ovarian carcinoma cancer cell lines (standard deviation of means were calculated for at least 3 repeats).

IC50 [μM]
R,R S,S
A2780 3.5 ± 1.3 4.8 ± 0.5
A2780cp 7.3 ± 2.1 4.7 ± 2.0
A2780adr 6.5 ± 3.2 4.3 ± 2.1

The induction of apoptosis vs. necrosis by the two enantiomers of L1Ti(OiPr)2 was investigated in vitro by double staining A2780 cells with annexin V-FITC and propidium iodide using flow cytometry. The cells were exposed to 8 μM (2xIC50) of racemic (R,R,Δ + S,S,Λ)-, R,R,Δ- or S,S,Λ-L1Ti(OiPr)2 isomers for 24 hours. The distribution of the populations between early and late apoptosis and necrosis is depicted in Fig. 7. In correlation with the cytotoxicity behavior on all tested cell lines, similar responses were observed for both enantiomers, showing similar induction of apoptosis within 24 hours. The racemic mixture had a negligible effect on the A2780 cells as anticipated by its inactivity, providing a distribution highly resembling that obtained in the control experiment (Supplementary Fig. S4).

Figure 7.

Figure 7

Effect of L1Ti(OiPr)2 (8 μM) ((a) control; (b) RR isomer; (c) SS isomer) on apoptosis (annexin V)/necrosis (propidium iodide) in human ovarian A2780 cells after 24 h of exposure using flow cytometry. Q1- necrotic (dead) cells; Q2- late apoptotic cells; Q3- viable cells; Q4- early apoptotic cells.

Conclusions

Herein we presented new chiral derivatives of anticancer salan Ti(IV) complexes based on the chiral cyclohexyl moiety. The most stable derivative of the examined compounds, with ortho-bromination on the aromatic rings and a tertiary amino bridge, exhibited no biological activity for all isomers. This may be explained by the additive effect of the steric groups, evincing that more stable is not always more active38,40,43. Inspecting the hydrolytic behavior of the least stable NH complex, it is evident that polynuclear complexes are obtained in water. Interestingly, the first product appears to be a dimer, where the cluster nuclearity increases with time to yield a tetranuclear species, that even after 30 days in water does not decompose significantly to give titanium dioxide. The pure enantiomers of this complex showed a marked cytotoxicity on all lines tested; nevertheless, different reactivity of the racemic mixture supports the notion that the polynuclear hydrolysis products are the cellular active species37,4144.

Comparing the behavior of the two active enantiomers in various aspects reveal no apparent difference, implying a similar mechanism35,36,55. Both are similarly active on all lines tested, and similarly induce apoptosis. It is thus evident that the Ti(IV) complexes perform through a different mechanism than that of cisplatin, adriamycin, or related drugs, providing them a potential advantage in the clinic. Additionally, similar reactivity of the two enantiomers may imply that tedious separation of enantiomers of chiral anticancer Ti(IV) complexes may be unnecessary, which is certainly another advantage. Nevertheless, identifying the biological target, if not necessarily chiral, and the mode of operation of these complexes remains enigmatic, and certainly merit additional mechanistic studies, currently underway in our laboratory.

Methods

Ligands L1–3H2 and bis(isopropoxo) titanium(IV) complexes L1–3Ti(OiPr)2 were synthesized according to published procedures37,38,48. All bis(isopropoxo) complexes were obtained in quantitative yields. Paraformaldehyde (97%), NaBH4 (97%), 1,2-trans-cyclohexanediamine (99%), and all substituted phenol and salicylaldehyde compounds (>96%) were purchased from Aldrich Chemical Company Inc., Fluka Riedel-DeHaen, Strem Chemicals Inc. or Alfa Aesar. Titanium tetra(isopropoxide) (97%) was purchased from Sigma Aldrich Chemical Company (Merck group). All solvents were dried over aluminum column on an MBraun drying system SPS-800. All experiments requiring dry atmosphere were performed in an M. Braun or LC-technologies dry-box or under nitrogen atmosphere using Schlenck line technique. NMR spectroscopic data were recorded with an AMX-400 MHz or AMX-500 MHz Bruker spectrometer. X-ray diffraction data were obtained with Bruker Smart Apex diffractometer. High resultion electrospray ionisation mass spectrometry were performed in the microanalytical laboratory in our institute. Specific optical rotation measurements were performed by Autopol I Automatic Polarimeter from Rudolph Research analytical and were calculated as the average of five measurements.

Cytotoxicity was measured on human colon HT-29 cancer cells (purchased from ATCC Inc.), human ovarian carcinoma A2780, human ovarian cisplatin-resistant carcinoma A2780cp, and human ovarian adriamycin-resistant A2780adr carcinoma cancer cell lines (purchased from ECACC Inc.) using the MTT assay as previously described54. Each measurement was repeated at least 3 × 3 times, namely, three repeats per plate, all repeated three times on different days (9 repeats altogether). Relative IC50 values with standard error of means were determined by a nonlinear regression of a variable slope (four parameters) model by Graph Pad Prism5.0 program. Kinetic hydrolysis studies by NMR were performed at RT as previously described25, using ca. 3.5 mM of the complex solution in THF-d8 and adding >1000 equiv. of D2O to give a final solution of 1:9 D2O/THF-d8. The t12 value is based on a pseudo first order fit for each compound. The results were verified by including p-dinitrobenzene (Sigma Aldrich Chemical Company Inc.) as an internal standard.

Apoptosis was measured using MEBCYTO apoptosis kit (annexin V-FITC kit, MBL). Cells were cultured in 6-well plates at density of 100,000 cells per well and allowed to attach overnight. The next day, the complex was added at 2xIC50 (8 μM) concentration and was incubated for 24 h. All procedures were conducted according to the manufacturers instructions. The samples were analyzed by flow cytometry (Becton-Dickinson Excallibar Fluorescence Activated Cell Sorter).

Rac-L1H2

3-Bromo-2-hydroxy-benzaldehyde (0.90 g, 4.5 mmol) and trans-1,2-cyclohexanediamine (0.3 mL, 2.2 mmol) in methanol (40 mL) were heated to reflux for 2 hours. The reaction was cooled to 0 °C and ca. 15 equivalents of NaBH4 (1.2 g, 33 mmol) were added. The precipitate was filtered and washed with cold methanol to give the desired product in 73% yield. ESI-HRMS (C20H24Br2N2O2 + H)+ m/z Calc.: 485.026 [M+] Found: 485.02690. 1H NMR (400 MHz, CDCl3): δ = 7.42 (d, J = 8.1 Hz, 1H; Ar), 7.01 (d, J = 7.6 Hz, 1H; Ar), 6.71 (t, J = 7.6 Hz, 1H; Ar), 4.07 (d, J = 13.6 Hz, 1H; CH2), 3.92 (d, J = 13.6 Hz, 1H; CH2), 2.54 (m, 1H; cy), 2.13 (m, 1H; cy), 1.74 (m, 1H; cy), 1.28 (m, 2H; cy) ppm. 13C NMR (125 MHz, CDCl3): δ = 154.6, 132.1, 127.2, 124.5, 120.0, 110.8, 59.7, 49.6, 30.7, 24.0 ppm.

R,R,Δ- (68%) and S,S,Λ-L1H2 (69%) were prepared similarly to rac-L1H2 from the optically pure trans-1,2-cyclohexanediamine. ESI-HRMS (C20H24Br2N2O2 + H)+ m/z Calc.: 485.026 [M+]; R,R,Δ-L1H2 found 485.02475, S,S,Λ-L1H2 found 485.03051. Optical rotation for R,R,Δ-L1H2: [α]D26 = −35 ± 1°, for S,S,Λ-L1H2: [α]D25 = 28 ± 2° (for both: c = 3 mg/mL CHCl3).

Rac-L2H2

5-Nitro-2-hydroxy-benzaldehyde (0.80 g, 4.8 mmol) and trans-1,2-cyclohexanediamine (0.3 mL, 2.4 mmol) in methanol (40 mL) were heated to reflux for 2 hours. The reaction was cooled to 0 °C and ca. 15 equivalents of NaBH4 (1.4 g, 36 mmol) were added. The precipitate was filtered and washed with cold methanol to give the desired product in 40% yield. ESI-HRMS (C20H24N4O6 + H)+ m/z Calc.: 417.177 [M+] Found: 417.17564. 1H NMR (400 MHz, DMSO): δ = 8.09 (s, 1H; Ar), 7.90 (dd, J = 4.6 Hz, 1H; Ar), 6.46 (s, 1H; Ar), 3.92 (d, J = 13.1 Hz, 1H; CH2), 3.77 (d, J = 13.2 Hz, 1H; CH2), 2.66 (m, 1H; cy), 2.07 (m, 1H; cy), 1.70 (m, 1H; cy), 1.23 (m, 2H; cy) ppm. 13C NMR (125 MHz, DMSO): δ = 132.2, 128.2, 127.0, 126.2, 125.6, 118.7, 58.9, 46.0, 29.5, 24.7 ppm.

R,R,Δ- (56%) and S,S,Λ-L2H2 (66%) were prepared similarly to rac-L2H2 from optically pure trans-1,2-cyclohexanediamine. ESI-HRMS (C20H24N4O6 + H)+ m/z Calc.: 417.177 [M+]; R,R,Δ-L1H2 found 417.17668, S,S,Λ-L1H2 found 417.17773. Optical rotation for R,R,Δ-L2H2: [α]D24 = −19 ± 1°, for S,S,Λ-L2H2 [α]D30 = 29 ± 1° (for both: c = 3 mg/mL DMSO).

Rac-L3H2

Rac-L1H2 (0.3 gr, 0.6 mmol) was dissolved in a mixture of acetonitrile and acetic acid (10 ml) and formaldehyde (15 mL, 0.41 mol) was added. The reaction was stirred at room temperature for ca. 2 hours to give a solid precipitate, and then cooled to 0 °C. Consequently, ca. 30 equivalents of NaBH4 (0.7 gr, 18 mmol) were added and the reaction was allowed to stand at room temperature overnight. NaOH 2M was added until pH 10 was reached. The precipitate was filtered and washed with water giving the desired product in 33% yield. ESI-HRMS (C22H28Br2N2O2 + H)+ m/z Calc.: 513.058 [M+] Found: 513.06056. 1H NMR (400 MHz, CDCl3): δ = 7.43 (d, J = 7.7 Hz, 1H; Ar), 6.95 (d, J = 7.4 Hz, 1H; Ar), 6.67 (t, J = 7.4 Hz, 1H; Ar), 3.86 (d, J = 13.7 Hz, 1H; CH2), 3.63 (d, J = 12.9 Hz, 1H; CH2), 2.70 (m, 1H; cy), 2.24 (s, 3 H; CH3), 2.01 (m, 1H; cy), 1.82 (m, 1H; cy), 1.21 (m, 2H; cy) ppm. 13C NMR (125 MHz, CDCl3): δ = 154.7, 132.5, 128.2, 123.9, 119.9, 110.9, 61.8, 56.5, 35.8, 25.2, 22.9 ppm.

R,R,Δ- (31%) and S,S,Λ-L3H2 (43%) were prepared similarly to rac-L3H2 from optically pure L1H2. ESI-HRMS (C22H28Br2N2O2 + H)+ m/z Calc.: 513.058 [M+]; R,R,Δ-L3H2 found 513.06862, S,S,Λ -L3H2 found 513.07273. Optical rotation for R,R,Δ-L3H2: [α]D33 = 29 ± 2°, for S,S,Λ-L3H2: [α]D29 = −26 ± 1° (for both: c = 3 mg/mL CHCl3).

Rac-L1Ti(OiPr)2

Ti(OiPr)4 (0.044 g, 0.15 mmol) was reacted with rac-L1H2 (0.075 g, 0.15 mmol) in dry THF at room temperature for 2 hours. After evaporation, the crude product was obtained in a >95% purity in quantitative yield. ESI-HRMS (C26H36Br2N2O4Ti + H)+ m/z Calc.: 649.058 [M+] Found: 649.05792. 1H NMR (400 MHz, CDCl3): δ = 7.45 (d, J = 7.8 Hz, 1H; Ar), 6.89 (d, J = 7.4 Hz, 1H; Ar), 6.52 (t, J = 7.6 Hz, 1H; Ar), 5.09 (sept, J = 6.1 Hz, 1H; CH), 4.87 (d, J = 14.2 Hz, 1H; CH2), 3.89 (d, J = 14.2 Hz, 1H; CH2), 2.22 (m, 1H; cy), 1.86 (m, 1H; cy), 1.65 (m, 1H; cy), 1.23 (m, 6H; CH3), 0.99 (m, 1H; cy), 0.85 (m, 1H; cy) ppm. 13C NMR (125 MHz, THF-d8): δ = 158.7, 131.4, 128.3, 124.3, 117.2, 112.3, 77.0, 62.7, 57.8, 48.9, 28.4, 25.4, 25.3 ppm.

R,R,Δ- and S,S,Λ-L1Ti(OiPr)2 were prepared similarly to rac-L1Ti(OiPr)2 from optically pure L1H2. ESI-HRMS (C26H36Br2N2O4Ti + H)+ m/z Calc.: 649.058 [M+]; R,R,Δ-L1Ti(OiPr)2 found 649.05792, S,S,Λ-L1Ti(OiPr)2 found 649.05792. Optical rotation for R,R,Δ-L1Ti(OiPr)2: [α]D24 = −75 ± 6°, for S,S,Λ-L1Ti(OiPr)2: [α]D27 = 88 ± 6° (for both: c = 0.6 mg/mL CHCl3).

Crystal data for Rac-L1Ti(OiPr)2

C26H36Br2N2O4Ti, Mr = 648.29, monoclinic, a = 13.052(1) Å, b = 15.173(1) Å, c = 13.742(1) Å, β = 93.513(2)°, V = 2716.3(4) Å3, T = 173(1) K, space group P21/n, Z = 4, μ (Mo-Kα) = 3.291 mm−1, 31165 reflections measured, 6490 unique (Rint = 0.0482). R(F2o) for [I > 2 σ(I)] = 0.0429, Rw for [I > 2 σ(I)] = 0.0861.

Rac-L2Ti(OiPr)2

Ti(OiPr)4 (0.058 g, 0.20 mmol) was reacted with rac-L2H2 (0.085 g, 0.20 mmol) in dry THF at room temperature overnight. After evaporation, the crude product was obtained in a >95% purity in quantitative yield. ESI-HRMS (C26H36N4O8Ti + H)+ m/z Calc.: 581.209 [M+] Found: 581.20880. 1H NMR (400 MHz, DMSO): δ = 8.08 (d, J = 2.1 Hz, 1H; Ar), 8.00 (dd, J = 7.2 Hz, 1H; Ar), 6.64 (d, J = 7.2 Hz, 1H; Ar), 4.79 (sept, J = 4.88 Hz, 1H; CH), 4.40 (d, J = 13.2 Hz, 1H; CH2), 4.02 (d, J = 10.6 Hz, 1H; CH2), 2.14 (m, 1H; cy), 2.03 (m, 1H; cy), 1.55 (m, 1H; cy), 1.14 (m, 6H; CH3), 1.04 (m, 1H; cy), 0.81 (m, 1H; cy) ppm. 13C NMR (125 MHz, DMSO): δ = 169.5, 137.5, 126.3, 125.4, 124.0, 118.5, 77.6, 67.5, 62.4, 58.5, 26.0, 25.6, 24.5 ppm.

R,R,Δ- and S,S,Λ-L2Ti(OiPr)2 were prepared similarly to rac-L2Ti(OiPr)2 from optically pure L2H2. ESI-HRMS (C26H36N4O8Ti + H)+ m/z Calc.: 581.209 [M+]; R,R,Δ-L2Ti(OiPr)2 found 581.20880, S,S,Λ-L2Ti(OiPr)2 found 581.21200. Optical rotation for R,R,Δ-L2Ti(OiPr)2: [α]D25 = −270 ± 10° (c = 0.1 mg/mL DMSO), for S,S,Λ- L2Ti(OiPr)2: [α]D19 = 249 ± 2° (c = 0.1 mg/mL DMSO).

Rac-L3Ti(OiPr)2

Ti(OiPr)4 (0.050 g, 0.17 mmol) was reacted with rac-L3H2 (0.090 g, 0.17 mmol) in dry THF at room temperature over weekend. After evaporation, the crude product was obtained in a >95% purity in quantitative yield. ESI-HRMS (C28H40Br2N2O4Ti + H)+ m/z Calc.: 677.089 [M+] Found: 677.08929. 1H NMR (400 MHz, CDCl3): δ = 7.46 (d, J = 6.2 Hz, 1H; Ar), 6.89 (d, J = 5.6 Hz, 1H; Ar), 6.54 (t, J = 6.1 Hz, 1H; Ar), 5.42 (sept, J = 4.96 Hz, 1H; CH), 4.71 (d, J = 10.9 Hz, 1H; CH2), 3.30 (d, J = 10.8 Hz, 1H; CH2), 2.55 (m, 1H; cy), 2.37 (s, 3H; CH3), 1.66 (m, 1H; cy), 1.56 (m, 1H; cy), 1.27 (m, 6H; CH3), 1.06 (m, 1H; cy), 0.74 (m, 1H; cy) ppm. 13C NMR (125 MHz, CDCl3): δ = 158.4, 132.8, 128.5, 127.2, 118.1, 112.7, 78.9, 68.0, 61.0, 57.8, 42.1, 25.6, 22.1, 19.2 ppm.

R,R,Δ- and S,S,Λ-L3Ti(OiPr)2 were prepared similarly to rac-L3Ti(OiPr)2 from optically pure L3H2. ESI-HRMS (C28H40Br2N2O4Ti + H)+ m/z Calc.: 677.089 [M+], R,R,Δ-L3Ti(OiPr)2 found 677.08929; (C28H40Br2N2O4Ti + Na)+ m/z Calc.: 699.071 [M+], S,S,Λ-L3Ti(OiPr)2 found 699.07039. Optical rotation for R,R,Δ-L3Ti(OiPr)2: [α]D27 = −350 ± 10° (c = 0.1 mg/mL CHCl3), for S,S,Λ-L3Ti(OiPr)2: [α]D24 = 350 ± 20° (c = 0.2 mg/mL CHCl3).

Crystal data for Rac-L3Ti(OiPr)2

C28H40Br2N2O4Ti, Mr = 676.34, monoclinic, a = 16.718(4) Å, b = 10.090(2) Å, c = 18.406(4) Å, β = 110.739(3)°, V = 2903.7(11) Å3, T = 173(1) K, space group P21/c, Z = 4, μ (Mo-Kα) = 3.082 mm−1, 29963 reflections measured, 6286 unique (Rint = 0.0664). R(F2o) for [I > 2 σ(I)] = 0.0825, Rw for [I > 2 σ(I)] = 0.1623.

Crystal data for S,S,Λ-L3Ti(OiPr)2

C28H40Br2N2O4Ti, Mr = 676.34, monoclinic, a = 10.0049(6) Å, b = 14.4108(9) Å, c = 10.2129(6) Å, β = 96.098(1)°, V = 1464.2(2) Å3, T = 173(1) K, space group P21, Z = 2, μ(Mo-Kα) = 3.057 mm−1, 16766 reflections measured, 6789 unique (Rint = 0.0231). R(F2o) for [I > 2 σ(I)] = 0.0259, Rw for [I > 2 σ(I)] = 0.0554.

The hydrolysis product Ti4(μ-O)4(S,S-L1)4 was obtained by dissolving ca. 20 mg of S,S,Λ-L1Ti(OiPr)2 in THF (6 mL) and adding >10,000 equivalents of H2O. The reaction was mixed for 30 days. The product was crystallized from diethyl ether. The structure contains disordered water molecules, for which H atoms were not detected.

Crystal data for Ti4(μ-O)4(S,S-L1)4

C80H88Br8N8O17.33Ti4, Mr = 2269.80, rhombohedral, a = 26.4920 (9) Å, c = 70.771 (3) Å, V = 43015(3) Å3, T = 173(1) K, space group R 3¯ c, Z = 18, μ (Mo-Kα) = 3.730 mm−1, 159243 reflections measured, 11525 unique (Rint = 0.1489). R(F2o) for [I > 2 σ(I)] = 0.0660, Rw for [I > 2 σ(I)] = 0.1270.

CCDC 1817336–1817339 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via https://www.ccdc.cam.ac.uk/structures/.

Electronic supplementary material

Acknowledgements

We thank Dr. Benny Bogoslavsky and Dr. Shmuel Cohen for solution of X-ray structures. Funding was received from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement 681243).

Author Contributions

M.M. and E.Y.T. conceived the experiments, M.M. executed the experiments and analyzed the results. All authors contributed to the writing and review of the paper.

Competing Interests

The authors declare no competing interests.

Footnotes

Electronic supplementary material

Supplementary information accompanies this paper at 10.1038/s41598-018-27735-0.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Korfel A, et al. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clinical Cancer Research. 1998;4:2701–2708. [PubMed] [Google Scholar]
  • 2.Christodoulou CV, et al. Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. Journal of Clinical Oncology. 1998;16:2761–2769. doi: 10.1200/JCO.1998.16.8.2761. [DOI] [PubMed] [Google Scholar]
  • 3.Mross K, et al. Phase I clinical trial of a day-1, -3, -5 every 3 weeks schedule with titanocene dichloride (mkt 5) in patients with advanced cancer: a study of the phase I study group of the association for medical oncology (AIO) of the german cancer society. Onkologie. 2000;23:576–579. doi: 10.1159/000055009. [DOI] [PubMed] [Google Scholar]
  • 4.Lümmen G, Sperling H, Luboldt H, Otto T, Rübben H. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemotherapy and Pharmacology. 1998;42:415–417. doi: 10.1007/s002800050838. [DOI] [PubMed] [Google Scholar]
  • 5.Kröger N, Kleeberg U, Mross K, Edler L, Hossfeld D. Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Oncology Research and Treatment. 2000;23:60–62. doi: 10.1159/000027075. [DOI] [Google Scholar]
  • 6.Heim, M. E., Flechtner, H. & Keppler, B. K. Clinical studies with budotitane—a new non-platinum metal complex for cancer therapy. In Ruthenium and Other Non-Platinum Metal Complexes in Cancer Chemotherapy, 217–223 (Springer, 1989).
  • 7.Schilling T, et al. Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane. Investigational New Drugs. 1995;13:327–332. doi: 10.1007/BF00873139. [DOI] [PubMed] [Google Scholar]
  • 8.Abeysinghe, P. M. & Harding, M. M. Antitumour bis (cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives. Dalton Transactions 3474–3482 (2007). [DOI] [PubMed]
  • 9.Caruso F, Rossi M, Pettinari C. Anticancer titanium agents. Expert Opinion on Therapeutic Patents. 2001;11:969–979. doi: 10.1517/13543776.11.6.969. [DOI] [Google Scholar]
  • 10.Caruso F, Rossi M. Antitumor titanium compounds and related metallocenes. Metal Ions in Biological Systems. 2004;42:353–384. [PubMed] [Google Scholar]
  • 11.Keppler, B., Friesen, C., Moritz, H., Vongerichten, H. & Vogel, E. Tumor-inhibiting bis (β-diketonato) metal complexes. budotitane, cis-diethoxybis (1-phenylbutane-1,3-dionato) titanium(IV). In Bioinorganic Chemistry, 97–127 (Springer, 1991).
  • 12.Tshuva EY, Ashenhurst JA. Cytotoxic titanium(IV) complexes: Renaissance. European Journal of Inorganic Chemistry. 2009;2009:2195–2195. doi: 10.1002/ejic.200990038. [DOI] [Google Scholar]
  • 13.Tshuva EY, Peri D. Modern cytotoxic titanium(IV) complexes; Insights on the enigmatic involvement of hydrolysis. Coordination Chemistry Reviews. 2009;253:2098–2115. doi: 10.1016/j.ccr.2008.11.015. [DOI] [Google Scholar]
  • 14.Kostova I. Titanium and vanadium complexes as anticancer agents. Anti-Cancer Agents. 2009;9:827–842. doi: 10.2174/187152009789124646. [DOI] [PubMed] [Google Scholar]
  • 15.Meléndez E. Titanium complexes in cancer treatment. Critical Reviews in Oncology. 2002;42:309–315. doi: 10.1016/S1040-8428(01)00224-4. [DOI] [PubMed] [Google Scholar]
  • 16.Loza-Rosas SA, et al. A ubiquitous metal, difficult to track: towards an understanding of the regulation of titanium(IV) in humans. Metallomics. 2017;9:346–356. doi: 10.1039/C6MT00223D. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cini M, Bradshaw TD, Woodward S. Using titanium complexes to defeat cancer: the view from the shoulders of titans. Chemical Society Reviews. 2017;46:1040–1051. doi: 10.1039/C6CS00860G. [DOI] [PubMed] [Google Scholar]
  • 18.Tshuva, E. Y. & Miller, M. Coordination complexes of titanium(IV) for anticancer therapy. In Metallo-Drugs: Development and Action of Anticancer Agents, vol. 18, 219–249 (Walter de Gruyter GmbH & Co KG, 2018). [DOI] [PubMed]
  • 19.Buettner KM, Valentine AM. Bioinorganic chemistry of titanium. Chemical Reviews. 2011;112:1863–1881. doi: 10.1021/cr1002886. [DOI] [PubMed] [Google Scholar]
  • 20.Strohfeldt K, Tacke M. Bioorganometallic fulvene-derived titanocene anti-cancer drugs. Chemical Society Reviews. 2008;37:1174–1187. doi: 10.1039/b707310k. [DOI] [PubMed] [Google Scholar]
  • 21.Koepf-Maier P, Koepf H. Non-platinum group metal antitumor agents. History, current status, and perspectives. Chemical Reviews. 1987;87:1137–1152. doi: 10.1021/cr00081a012. [DOI] [Google Scholar]
  • 22.Toney JH, Marks TJ. Hydrolysis chemistry of the metallocene dichlorides m (η5-C5H5)2Cl2, M = titanium, vanadium, or zirconium. Aqueous kinetics, equilibria, and mechanistic implications for a new class of antitumor agents. Journal of the American Chemical Society. 1985;107:947–953. doi: 10.1021/ja00290a033. [DOI] [Google Scholar]
  • 23.Caruso F, et al. (4-acyl-5-pyrazolonato) titanium derivatives: Oligomerization, hydrolysis, voltammetry, and DFT study. European Journal of Inorganic Chemistry. 2003;2003:3221–3232. doi: 10.1002/ejic.200300135. [DOI] [Google Scholar]
  • 24.Shavit M, Peri D, Manna CM, Alexander JS, Tshuva EY. Active cytotoxic reagents based on non-metallocene non-diketonato well-defined C2-symmetrical titanium complexes of tetradentate bis (phenolato) ligands. Journal of the American Chemical Society. 2007;129:12098–12099. doi: 10.1021/ja0753086. [DOI] [PubMed] [Google Scholar]
  • 25.Peri D, Meker S, Shavit M, Tshuva EY. Synthesis, characterization, cytotoxicity, and hydrolytic behavior of C2-and C1-symmetrical TiIV complexes of tetradentate diamine bis (phenolato) ligands: A new class of antitumor agents. Chemistry-A European Journal. 2009;15:2403–2415. doi: 10.1002/chem.200801310. [DOI] [PubMed] [Google Scholar]
  • 26.Peri D, Meker S, Manna CM, Tshuva EY. Different ortho and para electronic effects on hydrolysis and cytotoxicity of diamino bis (phenolato)“salan” Ti(IV) complexes. Inorganic Chemistry. 2011;50:1030–1038. doi: 10.1021/ic101693v. [DOI] [PubMed] [Google Scholar]
  • 27.Manna CM, Braitbard O, Weiss E, Hochman J, Tshuva EY. Cytotoxic salan–titanium(IV) complexes: High activity toward a range of sensitive and drug-resistant cell lines, and mechanistic insights. ChemMedChem. 2012;7:703–708. doi: 10.1002/cmdc.201100593. [DOI] [PubMed] [Google Scholar]
  • 28.Immel TA, Groth U, Huhn T, Öhlschläger P. Titanium salan complexes displays strong antitumor properties in vitro and in vivo in mice. PLoS One. 2011;6:e17869. doi: 10.1371/journal.pone.0017869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Immel TA, Groth U, Huhn T. Cytotoxic titanium salan complexes: surprising interaction of salan and alkoxy ligands. Chemistry-A European Journal. 2010;16:2775–2789. doi: 10.1002/chem.200902312. [DOI] [PubMed] [Google Scholar]
  • 30.Miller M, Braitbard O, Hochman J, Tshuva EY. Insights into molecular mechanism of action of salan titanium (IV) complex with in vitro and in vivo anticancer activity. Journal of Inorganic Biochemistry. 2016;163:250–257. doi: 10.1016/j.jinorgbio.2016.04.007. [DOI] [PubMed] [Google Scholar]
  • 31.Hancock SL, Gati R, Mahon MF, Tshuva EY, Jones MD. Heteroleptic titanium(IV) catecholato/piperazine systems and their anti-cancer properties. Dalton Transactions. 2014;43:1380–1385. doi: 10.1039/C3DT52583J. [DOI] [PubMed] [Google Scholar]
  • 32.Meker S, Manna CM, Peri D, Tshuva EY. Major impact of N-Methylation on cytotoxicity and hydrolysis of salan Ti(IV) complexes: sterics and electronics are intertwined. Dalton Trans. 2011;40:9802–9809. doi: 10.1039/c1dt11108f. [DOI] [PubMed] [Google Scholar]
  • 33.Glasner H, Tshuva EY. A marked synergistic effect in antitumor activity of salan titanium(IV) complexes bearing two differently substituted aromatic rings. Journal of the American Chemical Society. 2011;133:16812–16814. doi: 10.1021/ja208219f. [DOI] [PubMed] [Google Scholar]
  • 34.Glasner H, Tshuva EY. C1-symmetrical titanium(IV) complexes of salan ligands with differently substituted aromatic rings: Enhanced cytotoxic activity. Inorganic Chemistry. 2014;53:3170–3176. doi: 10.1021/ic500001j. [DOI] [PubMed] [Google Scholar]
  • 35.Cini M, et al. Enantiopure titanocene complexes–direct evidence for paraptosis in cancer cells. Metallomics. 2016;8:286–297. doi: 10.1039/C5MT00297D. [DOI] [PubMed] [Google Scholar]
  • 36.De la Cueva-Alique I, et al. Novel enantiopure cyclopentadienyl Ti(IV) oximato compounds as potential anticancer agents. Journal of Inorganic Biochemistry. 2016;156:22–34. doi: 10.1016/j.jinorgbio.2015.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Manna CM, Armony G, Tshuva EY. New insights on the active species and mechanism of cytotoxicity of salan-Ti(IV) complexes: A stereochemical study. Inorganic Chemistry. 2011;50:10284–10291. doi: 10.1021/ic201340m. [DOI] [PubMed] [Google Scholar]
  • 38.Manna CM, Armony G, Tshuva EY. Unexpected influence of stereochemistry on the cytotoxicity of highly efficient Ti(IV) salan complexes: New mechanistic insights. Chemistry-A European Journal. 2011;17:14094–14103. doi: 10.1002/chem.201102017. [DOI] [PubMed] [Google Scholar]
  • 39.Manna CM, Tshuva EY. Markedly different cytotoxicity of the two enantiomers of C2-symmetrical Ti(IV) phenolato complexes; mechanistic implications. Dalton Trans. 2010;39:1182–1184. doi: 10.1039/B920786B. [DOI] [PubMed] [Google Scholar]
  • 40.Miller M, Tshuva EY. Cytotoxic titanium(IV) complexes of chiral diaminobis (phenolato) ligands: Better combination of activity and stability by the bipyrrolidine moiety. European Journal of Inorganic Chemistry. 2014;2014:1485–1491. doi: 10.1002/ejic.201301463. [DOI] [Google Scholar]
  • 41.Meker S, Margulis-Goshen K, Weiss E, Magdassi S, Tshuva EY. High antitumor activity of highly resistant salan–titanium(IV) complexes in nanoparticles: An identified active species. Angewandte Chemie International Edition. 2012;124:10667–10669. doi: 10.1002/ange.201205973. [DOI] [PubMed] [Google Scholar]
  • 42.Meker S, et al. Anti-proliferative activity of nano-formulated phenolato titanium(IV) complexes against cancer cells. ChemMedChem. 2014;9:1294–1298. doi: 10.1002/cmdc.201400038. [DOI] [PubMed] [Google Scholar]
  • 43.Tzubery A, Tshuva EY. Cytotoxic titanium(IV) complexes of salalen-based ligands. European Journal of Inorganic Chemistry. 2017;2017:1695–1705. doi: 10.1002/ejic.201601200. [DOI] [Google Scholar]
  • 44.Tzubery, A., Melamed-Book, N. & Tshuva, E. Y. Fluorescent antitumor titanium(IV) salen complexes for cell imaging. Dalton Transactions (2018). [DOI] [PubMed]
  • 45.Yeori A, Groysman S, Goldberg I, Kol M. Diastereoisomerically selective enantiomerically pure titanium complexes of salan ligands: synthesis, structure, and preliminary activity studies. Inorganic Chemistry. 2005;44:4466–4468. doi: 10.1021/ic050745b. [DOI] [PubMed] [Google Scholar]
  • 46.Sergeeva, E., Kopilov, J., Goldberg, I. & Kol, M. Salan ligands assembled around chiral bipyrrolidine: predetermination of chirality around octahedral Ti and Zr centres. Chemical Communications 3053–3055 (2009). [DOI] [PubMed]
  • 47.Sergeeva E, Kopilov J, Goldberg I, Kol M. 2,2′-bipyrrolidine versus 1,2-diaminocyclohexane as chiral cores for helically wrapping diamine- diolate ligands. Inorganic Chemistry. 2009;48:8075–8077. doi: 10.1021/ic901367k. [DOI] [PubMed] [Google Scholar]
  • 48.Tshuva EY, Gendeziuk N, Kol M. Single-step synthesis of salans and substituted salans by mannich condensation. Tetrahedron Letters. 2001;42:6405–6407. doi: 10.1016/S0040-4039(01)01264-3. [DOI] [Google Scholar]
  • 49.Caruso F, et al. Synthesis, structure, and antitumor activity of a novel tetranuclear titanium complex. Journal of Medicinal Chemistry. 2000;43:3665–3670. doi: 10.1021/jm990539b. [DOI] [PubMed] [Google Scholar]
  • 50.Caruso F, Rossi M, Opazo C, Pettinari C. Structural features of antitumor titanium agents and related compounds. Bioinorganic Chemistry and Applications. 2005;3:317–329. doi: 10.1155/BCA.2005.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Hoffman RE, et al. Self-diffusion measurements of polycyclic aromatic hydrocarbon alkali metal salts. Journal of the Chemical Society, Perkin Transactions. 1998;2:1659–1664. doi: 10.1039/a800382c. [DOI] [Google Scholar]
  • 52.Valencia DP, González FJ. Understanding the linear correlation between diffusion coefficient and molecular weight. A model to estimate diffusion coefficients in acetonitrile solutions. Electrochemistry Communications. 2011;13:129–132. doi: 10.1016/j.elecom.2010.11.032. [DOI] [Google Scholar]
  • 53.Glasner H, Tshuva EY. Cytotoxic O-bridged inert titanium(IV) complexes of phenylenediamine-bis (phenolato) ligands. Inorganic Chemistry Communications. 2015;53:31–33. doi: 10.1016/j.inoche.2015.01.019. [DOI] [Google Scholar]
  • 54.Ganot, N., Meker, S., Reytman, L., Tzubery, A. & Tshuva, E. Y. Anticancer metal complexes: synthesis and cytotoxicity evaluation by the MTT assay. Journal of Visualized Experiments e50767 (2013). [DOI] [PMC free article] [PubMed]
  • 55.Cini M, Bradshaw TD, Woodward S, Lewis W. Asymmetric pentafulvene carbometalation—access to enantiopure titanocene dichlorides of biological relevance. Angew. Chemie International Edition. 2015;54:14179–14182. doi: 10.1002/anie.201508034. [DOI] [PubMed] [Google Scholar]
  • 56.Peri D, Manna CM, Shavit M, Tshuva EY. TiIV complexes of branched diamine bis (phenolato) ligands: Hydrolysis and cytotoxicity. European Journal of Inorganic Chemistry. 2011;2011:4896–4900. doi: 10.1002/ejic.201100725. [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES